← All trials
NCT06120491
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 21, 2023
- Primary completion
- Jan 19, 2028
- Completion date
- May 1, 2031
- First posted
- Nov 7, 2023
- Last posted
- Dec 20, 2023
- Enrollment
- 1800
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AstraZenecaLead sponsor
- Peter MacCallum Cancer CentreOverall official - principal investigator
- Peter MacCallum Cancer CentreOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.